Skip to main content
SpringerLink
Log in

Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year

  • Coronary Artery Disease
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Acute coronary disease remains a major cause of morbidity and mortality. Investigation in established and novel therapies aimed at treating acute coronary syndromes continues. The resulting increase in available options will present a significant challenge to practitioners determining the optimal regimen for specific patients. The addition of newer, more potent antiplatelet agents, such as prasugrel and possibly ticagrelor, will require careful patient selection and risk assessment for both recurrent ischemic events and bleeding. The likely addition of newer oral anticoagulants will require knowledge as to their specific characteristics and risk/benefit ratios. Incremental updates to guideline recommendations from established expert groups will be important in providing guidance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. World Health Organization: Atlas of Heart Disease and Stroke. Geneva: World Health Organization; 2004.

    Google Scholar 

  2. World Health Organization: Global Burden of Disease Study. Geneva: World Health Organization; 2004.

    Google Scholar 

  3. Anderson JL, Adams CD, Antman EM, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50(7):e1–e157. This is an important ACC/AHA guideline for the care of patients with NSTE-ACS.

    Google Scholar 

  4. Antman EM, Hand M, Armstrong PW, et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117(2):296–329.

    Google Scholar 

  5. Kushner FG, Hand M, Smith SC Jr, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120(22):2271–2306.This important ACC/AHA guideline update integrates new evidence regarding the use and timing of antiplatelet agents such as GPIs, clopidogrel, and prasugrel in addition to anticoagulants such as bivalirudin.

    Google Scholar 

  6. Patrono C, Bachmann F, Baigent C, et al.: Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 2004, 25(2):166–181.

    Article  PubMed  Google Scholar 

  7. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, et al.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28(13):1598–1660.

    Article  CAS  PubMed  Google Scholar 

  8. Van de Werf F, Bax J, Betriu A, et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008, 29(23):2909–2945.

    Article  PubMed  Google Scholar 

  9. Davi G, Patrono C: Platelet activation and atherothrombosis. N Engl J Med 2007, 357(24):2482–2494.

    Article  CAS  PubMed  Google Scholar 

  10. Kulkarni S, Dopheide SM, Yap CL, et al.: A revised model of platelet aggregation. J Clin Invest 2000, 105(6):783–791.

    Article  CAS  PubMed  Google Scholar 

  11. Mehta SR: CURRENT OASIS 7: A 2 × 2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. Proceedings of the European Society of Cardiology 2009 Congress. Barcelona, Spain; August 30-September 2, 2009.

  12. Mehta SR, Granger CB, Eikelboom JW, et al.: Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007, 50(18):1742–1751.

    Article  CAS  PubMed  Google Scholar 

  13. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345(7):494–502.

    Article  CAS  PubMed  Google Scholar 

  14. Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358(9281):527–533.

    Article  CAS  PubMed  Google Scholar 

  15. Mega JL, Close SL, Wiviott SD, et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354–362.

    Article  CAS  PubMed  Google Scholar 

  16. Ho PM, Maddox TM, Wang L, et al.: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301(9):937–944.

    Article  CAS  PubMed  Google Scholar 

  17. Cuisset T, Frere C, Quilici J, et al.: Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009, 54(13):1149–1153.

    Article  CAS  PubMed  Google Scholar 

  18. O’Donoghue ML, Braunwald E, Antman EM, et al.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009, 374(9694):989–997.

    Article  PubMed  Google Scholar 

  19. Bhatt DL: The COGENT trial. Proceedings of the Transcatheter Cardiovascular Therapeutics Conference. San Francisco, CA: September 24, 2009.

  20. US Food and Drug Administration: Clopidogrel (marketed as Plavix) and omeprazole (marketed as Prilosec)—drug interaction. Available at <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm>. Accessed December 2009.

  21. Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001–2015.

    Article  CAS  PubMed  Google Scholar 

  22. Montalescot G, Wiviott SD, Braunwald E, et al.: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373(9665):723–731.

    Article  CAS  PubMed  Google Scholar 

  23. Mega JL, Close SL, Wiviott SD, et al.: Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119(19):2553–2560.

    Article  CAS  PubMed  Google Scholar 

  24. Giugliano RP, White JA, Bode C, et al.: Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009, 360(21):2176–2190.

    Article  CAS  PubMed  Google Scholar 

  25. Wallentin L, Becker RC, Budaj A, et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045–1057.

    Article  CAS  PubMed  Google Scholar 

  26. Bhatt DL, Lincoff AM, Gibson CM, et al.: Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009, 361(24):2330–2341.

    Article  CAS  PubMed  Google Scholar 

  27. Harrington RA, Stone GW, McNulty S, et al.: Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361(24):2318–2329.

    Article  CAS  PubMed  Google Scholar 

  28. Stone GW, McLaurin BT, Cox DA, et al.: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355(21):2203–2216.

    Article  CAS  PubMed  Google Scholar 

  29. Stone GW, Witzenbichler B, Guagliumi G, et al.: Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358(21):2218–2230.

    Article  CAS  PubMed  Google Scholar 

  30. Mehran R, Lansky AJ, Witzenbichler B, et al.: Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009, 374(9696):1149–1159.

    Article  PubMed  Google Scholar 

  31. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, et al.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354(14):1464–1476.

    Article  CAS  PubMed  Google Scholar 

  32. Yusuf S, Mehta SR, Chrolavicius S, et al.: Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295(13):1519–1530.

    Article  CAS  PubMed  Google Scholar 

  33. Sabatine MS, Antman EM, Widimsky P, et al.: Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009, 374(9692):787–795.

    Article  CAS  PubMed  Google Scholar 

  34. Mega JL, Braunwald E, Mohanavelu S, et al.: Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374(9683):29–38.

    Article  CAS  PubMed  Google Scholar 

  35. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, et al.: Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009, 119(22):2877–2885.

    Article  PubMed  Google Scholar 

  36. Oldgren J: Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: RE-DEEM. Proceedings of the American Heart Association Scientific Sessions 2009. Orlando, FL; November 14–18, 2009.

Download references

Disclosure

Dr. Giugliano has received grant support from Daiichi-Sankyo, Merck, Novartis, and Schering-Plough; has been a consultant to Daiichi-Sankyo, Merck, Sanofi-Aventis, and Schering-Plough; and has received honoraria from Bristol-Myers Squibb, Merck, Sanofi-Aventis, and Schering-Plough. No other potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA

    Marc Bonaca MD & Robert P. Giugliano MD, SM

Authors
  1. Marc Bonaca MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert P. Giugliano MD, SM
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Bonaca MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonaca, M., Giugliano, R.P. Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. Curr Treat Options Cardio Med 12, 84–99 (2010). https://doi.org/10.1007/s11936-009-0059-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-009-0059-8

Keywords

Search

Navigation